(0.28%) 5 195.40 points
(0.25%) 38 950 points
(0.20%) 16 382 points
(-0.50%) $78.09
(0.59%) $2.21
(-0.24%) $2 325.60
(-0.24%) $27.55
(2.46%) $988.65
(-0.05%) $0.928
(0.39%) $10.87
(0.11%) $0.797
(0.11%) $91.45
0.00% $ 0.0642
Live Chart Being Loaded With Signals
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections...
Stats | |
---|---|
Dzisiejszy wolumen | 192.00 |
Średni wolumen | 69 044.00 |
Kapitalizacja rynkowa | 2.86M |
EPS | $0 ( 2024-01-01 ) |
Następna data zysków | ( $-0.0200 ) 2024-06-13 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.380 |
ATR14 | $0 (0.00%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-09-18 | Hamilton John F | Buy | 15 000 | Stock Options |
2023-09-18 | Windham-bannister Susan Richards | Buy | 15 000 | Stock Options |
2023-09-18 | Patzer Eric | Buy | 15 000 | Stock Options |
2023-09-18 | Truong Vu | Buy | 30 000 | Stock Options |
2023-09-18 | Jafri Hasan | Buy | 20 000 | Stock Options |
INSIDER POWER |
---|
79.21 |
Last 96 transactions |
Buy: 1 744 135 | Sell: 1 215 301 |
Aridis Pharmaceuticals Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
BPYPN | 0.963 |
ENG | 0.957 |
KZR | 0.957 |
MPAA | 0.956 |
USEG | 0.955 |
CLGN | 0.955 |
ARVL | 0.954 |
SLN | 0.953 |
SFNC | 0.951 |
CBAN | 0.95 |
10 Najbardziej negatywne korelacje | |
---|---|
NVDA | -0.954 |
CDNS | -0.949 |
NVCN | -0.947 |
UONE | -0.944 |
NVTS | -0.94 |
CMPO | -0.936 |
DKDCA | -0.936 |
SNPS | -0.934 |
LSCC | -0.933 |
STAY | -0.93 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Aridis Pharmaceuticals Finanse
Annual | 2022 |
Przychody: | $0 |
Zysk brutto: | $0 (0.00 %) |
EPS: | $-1.640 |
FY | 2022 |
Przychody: | $0 |
Zysk brutto: | $0 (0.00 %) |
EPS: | $-1.640 |
FY | 2021 |
Przychody: | $1.54M |
Zysk brutto: | $1.54M (100.00 %) |
EPS: | $-0.0270 |
FY | 2020 |
Przychody: | $0.00 |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $-2.44 |
Financial Reports:
No articles found.
Aridis Pharmaceuticals
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-320 is a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb, which is in Phase IIa clinical trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-501, an anti-infective therapy, which is in Phase I/IIa clinical trial to manage chronic lung infections in cystic fibrosis patients. In addition, it is developing AR-712 and AR-701, a cocktail of two fully human immunoglobulin 1, or IgG1, mAbs, which is in Phase I/II clinical for the treatment of mild to moderate non-hospitalized COVID-19 patients. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Los Gatos, California.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej